Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syros Pharmaceuticals Inc SYRS

Healthcare Biotechnology
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARa), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in... see more

Recent & Breaking News (NDAQ:SYRS)

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Business Wire April 9, 2024

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 2, 2024

Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Business Wire March 27, 2024

Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial

Business Wire March 25, 2024

Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024

Business Wire March 20, 2024

Syros to Participate in TD Cowen 44th Annual Health Care Conference

Business Wire February 27, 2024

Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene

Business Wire January 8, 2024

Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants

Business Wire December 19, 2023

Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Business Wire December 6, 2023

Syros to Participate in Upcoming Investor Conferences

Business Wire November 21, 2023

Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Business Wire November 14, 2023

Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

Business Wire November 7, 2023

Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company

Business Wire October 2, 2023

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 7, 2023

Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Business Wire August 8, 2023

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 4, 2023

Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

Business Wire August 1, 2023

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 5, 2023

Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference

Business Wire June 8, 2023

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 1, 2023